株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の血漿タンパク治療市場規模、シェア、動向分析:製品別(アルブミン、免疫グロブリン、第VIII因子)、用途別(血友病、PID、ITP)、地域別、セグメント別予測

Plasma Protein Therapeutic Market Size, Share & Trends Analysis Report By Product (Albumin, Immunoglobulin, Factor VIII), By Application (Hemophilia, PID, ITP), By Region, And Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 785972
出版日 ページ情報 英文 86 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
世界の血漿タンパク治療市場規模、シェア、動向分析:製品別(アルブミン、免疫グロブリン、第VIII因子)、用途別(血友病、PID、ITP)、地域別、セグメント別予測 Plasma Protein Therapeutic Market Size, Share & Trends Analysis Report By Product (Albumin, Immunoglobulin, Factor VIII), By Application (Hemophilia, PID, ITP), By Region, And Segment Forecasts, 2018 - 2025
出版日: 2018年12月14日 ページ情報: 英文 86 Pages
概要

当レポートでは、世界の血漿タンパク治療市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査範囲

第2章 エグゼクティブサマリー

第3章 市場の定義

第4章 業界見通し

  • 市場セグメンテーション
  • 市場促進因子分析
  • 市場阻害因子分析

第5章 競合・ベンダー環境

  • 主要企業リスト
  • 戦略的取り組み
  • 企業市場シェア
  • パイプライン分析

第6章 ビジネス環境分析

第7章 法規制上の見通し

第8章 製品別ビジネス分析

  • 動向分析
  • 免疫グロブリン
  • アルブミン
  • 血漿由来第VIII因子
  • その他

第9章 用途別ビジネス分析

  • 動向分析
  • 血友病
  • 原発性免疫不全症
  • 特発性血小板減少性紫斑病
  • その他

第10章 地域別ビジネス分析

  • 動向分析
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第11章 企業プロファイル

  • Csl Behring Llc
  • Grifols
  • Shire Plc.
  • Octapharma Ag
  • Biotest Ag.
  • Kedrion S.P.A
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Plasma Protein Therapeutics Market, By Region, 2014 - 2025 (USD Millions)
  • Table 3 North America Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 4 North America Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 5 U.S. Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 6 U.S. Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 7 Canada Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 8 Canada Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 9 Europe Plasma Protein Therapeutics Market, By Region, 2014 - 2025 (USD Millions)
  • Table 10 Europe Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 11 Europe Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 12 U.K. Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 13 U.K. Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 14 Germany Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 15 Germany Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 16 Asia Pacific Plasma Protein Therapeutics Market, By Region, 2014 - 2025 (USD Millions)
  • Table 17 Asia Pacific Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 18 Asia Pacific Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 19 China Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 20 China Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 21 India Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 22 India Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 23 Latin America Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 24 Latin America Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 25 Brazil Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 26 Brazil Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 27 Mexico Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 28 Mexico Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 29 MEA Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 30 MEA Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)
  • Table 31 South Africa Plasma Protein Therapeutics Market, By Product, 2014 - 2025 (USD Millions)
  • Table 32 South Africa Plasma Protein Therapeutics Market, By Application, 2014 - 2025 (USD Millions)

List of Figures

  • Fig. 1 Plasma protein therapeutics market segmentation
  • Fig. 2 Plasma protein therapeutics market segmentation
  • Fig. 3 Plasma protein therapeutics market driver impact
  • Fig. 4 Plasma fraction demand in 2010
  • Fig. 5 Global population growth, by age-group, 2012 - 2020 (Million)
  • Fig. 6 Plasma protein therapeutics market restraint impact
  • Fig. 7 Company Market Share Analysis: Plasma Protein Therapeutics Market
  • Fig. 8 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 SAHPRA: Organization Structure
  • Fig. 11 Plasma protein therapeutics market: Type outlook and key takeaways
  • Fig. 12 Plasma protein therapeutics, product movement analysis
  • Fig. 13 Immunoglobulin market estimates and forecast, 2014 - 2025
  • Fig. 14 Albumin market estimates and forecast, 2014 - 2025
  • Fig. 15 Factor VIII market estimates and forecast, 2014 - 2025
  • Fig. 16 Others market estimates and forecast, 2014 - 2025
  • Fig. 17 Plasma protein therapeutics market application outlook and key takeaways
  • Fig. 18 Plasma protein therapeutics, application movement analysis
  • Fig. 19 Hemophilia market estimates and forecast, 2014 - 2025
  • Fig. 20 Primary immunodeficiency market estimates and forecast, 2014 - 2025
  • Fig. 21 Idiopathic thrombocytopenic market estimates and forecast, 2014 - 2025
  • Fig. 22 Others market estimates and forecast, 2014 - 2025
  • Fig. 23 Plasma proteins therapeutics market: Regional outlook and key takeaways
  • Fig. 24 Plasma protein therapeutics market: Regional movement analysis
  • Fig. 25 North America
  • Fig. 26 North America market estimates and forecast, 2014 - 2025
  • Fig. 27 U.S. market estimates and forecast, 2014 - 2025
  • Fig. 28 Canada market estimates and forecast, 2014 - 2025
  • Fig. 29 Europe
  • Fig. 30 Europe market estimates and forecast, 2014 - 2025
  • Fig. 31 Germany market estimates and forecast, 2014 - 2025
  • Fig. 32 UK market estimates and forecast, 2014 - 2025
  • Fig. 33 Asia-Pacific
  • Fig. 34 Asia-Pacific market estimates and forecast, 2014 - 2025
  • Fig. 35 China market estimates and forecast, 2014 - 2025
  • Fig. 36 India market estimates and forecast, 2014 - 2025
  • Fig. 37 Latin America
  • Fig. 38 Latin America market estimates and forecast, 2014 - 2025
  • Fig. 39 Brazil market estimates and forecast, 2014 - 2025
  • Fig. 40 Mexico market estimates and forecast, 2014 - 2025
  • Fig. 41 Middle East & Africa
  • Fig. 42 Middle East market estimates and forecast, 2014 - 2025
  • Fig. 43 South Africa market estimates and forecast, 2014 - 2025
目次
Product Code: GVR-2-68038-664-6

The global plasma protein therapeutics market size is expected to reach USD 33.15 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 4.8% over the forecast period. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.

Plasma-derived proteins are primarily used as replacement therapies to treat chronic, rare diseases. Patients that rely on these medications require regular injections or infusions throughout their lives. While there are more than 250 products derived from plasma, key players generally rely on Immunoglobulin (IG), albumin, and factor VIII to drive sales and profitability.

Over the past decade, the plasma protein therapeutics market has grown lucratively with immunoglobulin capturing the major market share. Demand for plasma derived-products is driven by rising disease prevalence, geriatric population, and improved access to drugs in emerging markets. Approvals of new plasma-derived therapies are anticipated to further fuel the demand. Developing countries such as China and Brazil offer new investment avenues to the global market giants.

Further key findings from the report suggest:

Germany leads the European market, supported by high demand for blood components, presence of key players, large addressable population, and rising disease prevalence

Demand for immunoglobulin is expected to continue rising owing to prevalence of primary immunodeficiencies, usage in new indications, and ease of administration

Non-plasma based recombinant therapies are likely to compete with plasma-derived products in the factor VIII market

Asia Pacific is expected to exhibit high growth over the forecast period fueled by increasing healthcare expenditure, presence of a large number patients. improved ratio of patients suffering from disease and patients receiving treatment, low-cost production of drugs, and improvement in diagnostic technology.

Major players operating in the plasma protein therapeutics market include CSL Behring, Grifols, S.A., Shire Plc, Octapharma AG, Biotest AG, and Kedrion S.P.A. Regional expansion, broad product portfolio, and merger & acquisitions are chief strategic undertakings adopted by key players.

Table of Contents

Chapter 1 Report Scope

  • 1.1 Research Methodology
  • 1.2 Market Scope
  • 1.3 Regional Scope
  • 1.4 Estimates And Forecasts Timeline

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Definitions

Chapter 4 Industry Outlook

  • 4.1 Market Segmentation
  • 4.2 Market Driver Analysis
    • 4.2.1 Increase In Usage Of Plasma In Pharmaceutical Industry
    • 4.2.2 Downstream Process Optimization
    • 4.2.3 Increasing Geriatric Population
    • 4.2.4 Expanding Applications
  • 4.3 Market Restraint Analysis
    • 4.3.1 Manufacturing And Storage Issues In Developing Regions
    • 4.3.2 Slower Approval Procedures

Chapter 5 Competitive And Vendor Landscape

  • 5.1 List Of Key Companies
  • 5.2 List Of Strategic Initiatives
  • 5.3 Company Market Share
  • 5.4 Pipeline Analysis: Albumin, Phase III
  • 5.5 Pipeline Analysis: Globulin, Phase III
  • 5.6 Pipeline Analysis: Fibrinogen, Phase III

Chapter 6 Business Environmental Analysis

  • 6.1 Business Environment Analysis Tools
    • 6.1.1 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 6.1.2 Porter's Five Forces Analysis

Chapter 7 Regulatory Outlook

  • 7.1 Regulatory Landscape
    • 7.1.1 U.S.
    • 7.1.2 Canada
    • 7.1.3 Uk
    • 7.1.4 Germany
    • 7.1.5 Japan
    • 7.1.6 China
    • 7.1.7 Mexico
    • 7.1.8 Brazil
    • 7.1.9 Uae
    • 7.1.10 South Africa

Chapter 8 Product Business Analysis

  • 8.1 Plasma Protein Therapeutics Market: Product Movement Analysis
  • 8.2 Immunoglobulin
    • 8.2.1 Immunoglobulin Market Estimates And Forecast, 2014 - 2025
  • 8.3 Albumin
    • 8.3.1 Albumin Market Estimates And Forecast, 2014 - 2025
  • 8.4 Plasma Derived Factor Viii
    • 8.4.1 Plasma Derived Factor Viii Market Estimates And Forecast, 2014 - 2025
  • 8.5 Others
    • 8.5.1 Others Market Estimates And Forecast, 2014 - 2025

Chapter 9 Application Business Analysis

  • 9.1 Plasma Protein Therapeutics Market: Application Movement Analysis
  • 9.2 Hemophilia
    • 9.2.1 Hemophilia Market Estimates And Forecast, 2014 - 2025
  • 9.3 Primary Immunodeficiencies
    • 9.3.1 Primary Immunodeficiency Market Estimates And Forecast, 2014 - 2025
  • 9.4 Idiopathic Thrombocytopenic Purpura
    • 9.4.1 Idiopathic Thrombocytopenic Market Estimates And Forecast, 2014 - 2025
  • 9.5 Others
    • 9.5.1 Others Market Estimates And Forecast, 2014 - 2025

Chapter 10 Regional Business Analysis

  • 10.1 Plasma Protein Therapeutics Market: Regional Movement Analysis
  • 10.2 North America
    • 10.2.1 North America Market Estimates And Forecast, 2014 - 2025
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. Market Estimates And Forecast, 2014 - 2025
    • 10.2.3 Canada
      • 10.2.3.1 Canada Market Estimates And Forecast, 2014 - 2025
  • 10.3 Europe
    • 10.3.1 Europe Market Estimates And Forecast, 2014 - 2025
    • 10.3.2 Germany
      • 10.3.2.1 Germany Market Estimates And Forecast, 2014 - 2025
    • 10.3.3 Uk
      • 10.3.3.1 Uk Market Estimates And Forecast, 2014 - 2025
  • 10.4 Asia-Pacific
    • 10.4.1 Asia-Pacific Market Estimates And Forecast, 2014 - 2025
    • 10.4.2 China
      • 10.4.2.1 China Market Estimates And Forecast, 2014 - 2025
    • 10.4.3 India
      • 10.4.3.1 India Market Estimates And Forecast, 2014 - 2025
  • 10.5 Latin-America
    • 10.5.1 Latin America Market Estimates And Forecast, 2014 - 2025
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil Market Estimates And Forecast, 2014 - 2025
    • 10.5.3 Mexico
      • 10.5.3.1 Mexico Market Estimates And Forecast, 2014 - 2025
  • 10.6 Middle East & Africa
    • 10.6.1 Middle-East And Africa Market Estimates And Forecast, 2014 - 2025
    • 10.6.2 South Africa
      • 10.6.2.1 South Africa Market Estimates And Forecast, 2014 - 2025

Chapter 11 Company Profile

  • 11.1 Csl Behring Llc
    • 11.1.1 Company Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Benchmarking
    • 11.1.4 Strategic Initiatives
  • 11.2 Grifols
    • 11.2.1 Company Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Benchmarking
    • 11.2.4 Strategic Initiatives
  • 11.3 Shire Plc.
    • 11.3.1 Company Overview
    • 11.3.2 Financial Performance
      • 11.3.2.1 Product Benchmarking
      • 11.3.2.2 Strategic Initiatives
  • 11.4 Octapharma Ag
    • 11.4.1 Company Overview
    • 11.4.2 Financial Performance
      • 11.4.2.1 Product Benchmarking
      • 11.4.2.2 Strategic Initiatives
  • 11.5 Biotest Ag.
    • 11.5.1 Company Overview
    • 11.5.2 Financial Performance
      • 11.5.2.1 Product Benchmarking
      • 11.5.2.2 Strategic Initiatives
  • 11.6 Kedrion S.P.A
    • 11.6.1 Company Overview
    • 11.6.2 Financial Performance
      • 11.6.2.1 Product Benchmarking
      • 11.6.2.2 Strategic Initiatives
Back to Top